BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

...the interface of immunity and metabolism, including LANCL2, NLRX1 and PLXDC2.Lead program BT-11, which targets LANCL2...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...lead product BT-11 for ulcerative colitis and Crohn’s disease; the first-in-class oral small molecule targets lanC like 2 (LANCL2)...
BioCentury | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

...it will go toward the Phase II inflammatory bowel disease trials of the first-in-class oral LANCL2...
...in 1H20 for ulcerative colitis and Crohn's, said Bassaganya-Riera. The company's pipeline also contains additional LANCL2...
...the financing, RTW’s Rod Wong and Perceptive’s Konstantin Poukalov joined Landos’ board. Targets: LANCL2 - LanC like 2...
BioCentury | Apr 20, 2018
Emerging Company Profile

Clear for Landos

...Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and...
...binds to LANCL2, which leads to downstream activation of cAMP signaling and various anti-inflammatory pathways. LANCL2...
...midyear. According to BioCentury’s BCIQ database, there are no clinical stage IBD candidates that target LANCL2...
BioCentury | Sep 22, 2017
Financial News

Landos spins out of Xontogeny accelerator

...the company files an IND for lead candidate BT-11 next year. BT-11 is an oral LanC like 2 (LANCL2)...
...the accelerator. Garabedian joined Landos’ board. Landos Biopharma Inc. , Blacksburg, Va. Alicia Parker BT-11 Landos Biopharma Inc. Xontogeny LLC LanC like 2 (LANCL2)...
BioCentury | Sep 21, 2017
Financial News

Landos spins out of Xontogeny accelerator

...the company files an IND for lead candidate BT-11 next year. BT-11 is an oral LanC like 2 (LANCL2)...
...declined to disclose the number of companies in the accelerator. Garabedian joined Landos’ board. Virginia Li Xontogeny LLC LanC like 2 (LANCL2) BT-11 Landos...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Autoimmune disease

...benzoimidazolylpyridine-based LANCL2 agonist that could help treat IBD. In silico screening of benzoimidazole analogs for LANCL2...
...followed by chemical synthesis and testing of hits in vitro yielded a compound that bound LANCL2...
...include testing the safety and efficacy of the compound in additional models of IBD. TARGET/MARKER/PATHWAY: LanC like 2 (LANCL2)...
Items per page:
1 - 7 of 7